$40.97
-3.06-6.95%
Pre-Market: 7:15 PM EDT
15 minutes delayed
Comments
Loading...
Dyne Therapeutics
DYNNASDAQ
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Dyne Therapeutics (NASDAQ:DYN) Stock, Analyst Ratings, Price Targets, Forecasts
Dyne Therapeutics Inc has a consensus price target of $42.5 based on the ratings of 10 analysts. The high is $56 issued by Raymond James on January 4, 2024. The low is $29 issued by Piper Sandler on March 6, 2024. The 3 most-recent analyst ratings were released by JP Morgan, Chardan Capital, and Jefferies on July 9, 2024, May 21, 2024, and May 20, 2024, respectively. With an average price target of $42.33 between JP Morgan, Chardan Capital, and Jefferies, there's an implied 3.33% upside for Dyne Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
JP Morgan
Chardan Capital
Jefferies
HC Wainwright & Co.
Oppenheimer
1calculated from analyst ratings
Analyst Ratings for Dyne Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/09/2024 | Buy Now | 4.95% | JP Morgan | Tessa Romero | $39 → $43 | Maintains | Overweight | Get Alert |
| 05/21/2024 | Buy Now | 2.51% | Chardan Capital | Keay Nakae | $31 → $42 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 2.51% | Jefferies | — | $36 → $42 | Maintains | Buy | Get Alert |
| 05/20/2024 | Buy Now | 17.16% | HC Wainwright & Co. | Andrew Fein | $46 → $48 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | -24.33% | Chardan Capital | Keay Nakae | $31 → $31 | Maintains | Buy | Get Alert |
| 05/06/2024 | Buy Now | 14.72% | Oppenheimer | Francois Brisebois | $47 → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 05/03/2024 | Buy Now | -12.13% | HC Wainwright & Co. | Andrew Fein | — | Reiterates | Buy → Buy | Get Alert |
| 04/30/2024 | Buy Now | -2.37% | Morgan Stanley | Michael Ulz | → $40 | Initiates | → Overweight | Get Alert |
| 03/26/2024 | Buy Now | 14.72% | Oppenheimer | Francois Brisebois | $47 → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 03/08/2024 | Buy Now | -24.33% | Chardan Capital | Keay Nakae | $20 → $31 | Maintains | Buy | Get Alert |
| 03/07/2024 | Buy Now | -9.69% | Guggenheim | Debjit Chattopadhyay | $33 → $37 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | -12.13% | HC Wainwright & Co. | Andrew Fein | → $36 | Reiterates | Buy → Buy | Get Alert |
| 03/06/2024 | Buy Now | 0.07% | Stifel | Paul Matteis | $35 → $41 | Maintains | Buy | Get Alert |
| 03/06/2024 | Buy Now | -29.22% | Piper Sandler | Edward Tenthoff | $27 → $29 | Maintains | Overweight | Get Alert |
| 03/05/2024 | Buy Now | 14.72% | Oppenheimer | Francois Brisebois | $44 → $47 | Reiterates | Outperform → Outperform | Get Alert |
| 02/20/2024 | Buy Now | -12.13% | HC Wainwright & Co. | Andrew Fein | → $36 | Initiates | → Buy | Get Alert |
| 01/04/2024 | Buy Now | 36.69% | Raymond James | Steven Seedhouse | $27 → $56 | Maintains | Strong Buy | Get Alert |
| 08/09/2023 | Buy Now | -46.3% | JP Morgan | Tessa Romero | $20 → $22 | Maintains | Overweight | Get Alert |
| 08/04/2023 | Buy Now | -51.18% | Chardan Capital | Keay Nakae | → $20 | Reiterates | Buy → Buy | Get Alert |
| 03/03/2023 | Buy Now | -51.18% | Chardan Capital | Keay Nakae | $17 → $20 | Maintains | Buy | Get Alert |
| 02/27/2023 | Buy Now | -34.1% | Raymond James | Steven Seedhouse | $16 → $27 | Upgrade | Outperform → Strong Buy | Get Alert |
| 02/15/2023 | Buy Now | -17.01% | Oppenheimer | Francois Brisebois | → $34 | Initiates | → Outperform | Get Alert |
| 01/26/2023 | Buy Now | -19.45% | Guggenheim | Debjit Chattopadhyay | → $33 | Initiates | → Buy | Get Alert |
| 11/29/2022 | Buy Now | -56.07% | JP Morgan | Tessa Romero | $24 → $18 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | -60.95% | Raymond James | Steven Seedhouse | $15 → $16 | Maintains | Outperform | Get Alert |
| 07/20/2022 | Buy Now | -58.51% | Chardan Capital | Keay Nakae | → $17 | Initiates | → Buy | Get Alert |
| 07/12/2022 | Buy Now | -63.39% | Raymond James | Steven Seedhouse | → $15 | Initiates | → Outperform | Get Alert |
| 05/23/2022 | Buy Now | -70.71% | Piper Sandler | Edward Tenthoff | $16 → $12 | Maintains | Overweight | Get Alert |
FAQ
What is the target price for Dyne Therapeutics (DYN) stock?
The latest price target for Dyne Therapeutics (NASDAQ:DYN) was reported by JP Morgan on July 9, 2024. The analyst firm set a price target for $43.00 expecting DYN to rise to within 12 months (a possible 4.95% upside). 19 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Dyne Therapeutics (DYN)?
The latest analyst rating for Dyne Therapeutics (NASDAQ:DYN) was provided by JP Morgan, and Dyne Therapeutics maintained their overweight rating.
When was the last upgrade for Dyne Therapeutics (DYN)?
The last upgrade for Dyne Therapeutics Inc happened on February 27, 2023 when Raymond James raised their price target to $27. Raymond James previously had an outperform for Dyne Therapeutics Inc.
When was the last downgrade for Dyne Therapeutics (DYN)?
There is no last downgrade for Dyne Therapeutics.
When is the next analyst rating going to be posted or updated for Dyne Therapeutics (DYN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Dyne Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Dyne Therapeutics was filed on July 9, 2024 so you should expect the next rating to be made available sometime around July 9, 2025.
Is the Analyst Rating Dyne Therapeutics (DYN) correct?
While ratings are subjective and will change, the latest Dyne Therapeutics (DYN) rating was a maintained with a price target of $39.00 to $43.00. The current price Dyne Therapeutics (DYN) is trading at is $40.97, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.